AI-based docking and affinity prediction allow us to design antibodies on predetermined epitopes, chosen to trigger the desired biological effect, and high efficacy.
We evaluate inter-molecular (off-targets) and inter-species reactivity, in order to limit the side effects (cross-reactivity) and anticipate binding for pre-clinical development (cross-specificity).
Antibodies sequences liabilities (PTMs, aggregation motifs...) are evaluated during the molecular design, to optimize stability and limit immunogenicity.
Lead candidates design in 21 days allows you to strengthen, parallelize and multiply your discovery programs.
Do not risk to spend months never finding a good lead. Know fast, retry fast and succeed fast!
No back-and-forth optimization of your hits. Start immediately with the lead candidates that are ready for development.
Combining expertises is key: computational science, biology and software development are essential skills at MAbSilico